Immunome Inc.
IMNM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMNM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMNM
Immunome Inc. is a clinical-stage oncology company advancing a pipeline of targeted therapies, including the lead asset varegacestat in a Phase 3 trial for desmoid tumors, and a portfolio of antibody-drug conjugates.
Key risk: Clinical trial failure
BioSniper Score
Based on 6 of 6 signals
Market Cap
$3.13B
Cash Runway
24.8 moLead Asset
IM-1021 (Phase 1)Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 8 clinical trials · 1 catalyst for Immunome Inc..
Immunome Inc. is a clinical-stage oncology company advancing a pipeline of targeted therapies, including the lead asset varegacestat in a Phase 3 trial for desmoid tumors, and a portfolio of antibody-drug conjugates.
- Cash and equivalents of $217.9M as of 2026-06-30 [sec].
- Lead candidate varegacestat is in a Phase 3 RINGSIDE trial; an NDA filing was planned for Q2 2026 [sec · filed 2026-04-24].
- ADC portfolio includes IM-1021 (Phase 1), IM-1617, IM-1340, and IM-1335, all using a proprietary TOP1 inhibitor payload (HC74) [sec · filed 2026-04-24].
- Net loss of $73.1M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $269.3M as of 2026-06-30 [sec].
What works
- Lead asset varegacestat is in a pivotal Phase 3 trial (RINGSIDE) with a planned NDA submission, representing a clear near-term regulatory catalyst [sec · filed 2026-04-24].
- The ADC portfolio uses a proprietary TOP1 inhibitor payload (HC74) and targets novel or underexplored antigens, potentially offering differentiated profiles [sec · filed 2026-04-24].
- Strong cash position of $217.9M as of 2026-06-30 provides runway for ongoing clinical development and operations [sec].
What to weigh
- The company has no approved products and has generated zero revenue as of 2026-06-30, relying entirely on financing to fund operations [sec].
- Net loss of $73.1M for the six months ended 2026-06-30 reflects high R&D and operational spending typical of a clinical-stage biotech [sec].
- Varegacestat's success is highly dependent on positive Phase 3 data and regulatory approval; any delay or negative outcome would materially impact the company [sec · filed 2026-04-24].
- The company will need additional financing to support commercialization of varegacestat (if approved) and continued pipeline development [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Varegacestat Phase 3 trial and planned NDA filing
“Successful execution of the Phase 3 RINGSIDE trial and completion of critical manufacturing and non-clinical pharmacology activities position us to support our planned NDA filing in the second quarter of 2026.”
SEC filings · April 24, 2026
ADC portfolio with proprietary payload
“Each of these ADC programs incorporates our proprietary TOP1 inhibitor payload (HC74) and is designed with a differentiated profile”
SEC filings · April 24, 2026
Cash position and runway
“We expect that our existing cash and cash equivalents as of March 31, 2026 will be sufficient to fund our current and planned operating expenses and capital expenditures for at least 12 months from the filing date of this Quarterly Report on Form 10-Q.”
SEC MD&A · May 12, 2026
No revenue and reliance on financing
“We will need additional financing to support our continuing operations and pursue our research and development strategy and commercialization of varegacestat, if approved.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2026-12-01 · Phase3_Topline — Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing — Topline results from the pivotal Phase 3 RINGSIDE trial of varegacestat in desmoid tumors will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- Clinical trial failure — Negative or delayed Phase 3 RINGSIDE results for varegacestat would severely impact the company's prospects [sec · filed 2026-04-24].
- Regulatory approval uncertainty — Even with positive data, FDA approval of varegacestat is not guaranteed and could be delayed or denied [sec · filed 2026-04-24].
- Need for additional capital — The company will require further financing to fund commercialization and pipeline development, with no guarantee of availability [sec_mda · as of 2026-05-12].
- Early-stage pipeline — ADC programs are in Phase 1 or preclinical stages, with no clinical proof-of-concept yet [sec · filed 2026-04-24].
What to watch
- Phase 3 RINGSIDE topline data for varegacestat, expected by late 2026 [upcoming catalysts].
- NDA submission for varegacestat, previously planned for Q2 2026 [sec · filed 2026-04-24].
- Phase 1 data for ADC IM-1021 [sec · filed 2026-04-24].
- Cash burn rate and any new financing or business development activities [sec_mda · as of 2026-05-12].
Sources: SEC filings · SEC MD&A · Generated August 25, 2026 · How we verify sources →
Run Immunome Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immunome Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
24.8 months
D/E 0.08 · 0% dilution
Lead: Phase 1
3 candidates
1 upcoming, next in ~93d
7 buys · 25 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
198
Total value held
$2.19B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,969,954 | $371.1M |
| vanguard capital management llc | 8,859,394 | $193.8M |
| blackrock, inc. | 8,168,674 | $178.6M |
| state street corp | 5,399,901 | $118.1M |
| primecap management co/ca/ | 4,788,231 | $104.7M |
| wellington management group llp | 4,731,977 | $103.5M |
| driehaus capital management llc | 4,099,901 | $89.7M |
| enavate sciences gp, llc | 3,613,799 | $79.0M |
| woodline partners lp | 3,150,796 | $68.9M |
| morgan stanley | 2,841,589 | $62.1M |
Showing top 10 of 198 institutional holders of Immunome Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 17.0%
- Days to cover
- 12.4
- Shares short
- 18,604,286
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMNM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Immunome Inc.?
Immunome Inc. is a clinical-stage oncology company advancing a pipeline of targeted therapies, including the lead asset varegacestat in a Phase 3 trial for desmoid tumors, and a portfolio of antibody-drug conjugates.
What is Immunome Inc.'s lead drug candidate?
Immunome Inc.'s most advanced tracked candidate is IM-1021 (Phase 1) for Solid Malignancies.
What is Immunome Inc.'s next catalyst?
Immunome Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing " — expected December 1, 2026.
Who is the CEO of Immunome Inc.?
Dr. Clay B. Siegall Ph.D. is the chief executive officer of Immunome Inc. (IMNM).
Where is Immunome Inc. headquartered?
Immunome Inc. (IMNM) is headquartered in Bothell, WA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.